BioVie (NASDAQ: BIVI) stock surged over 50% on Friday after the company revealed encouraging data from two clinical trials involving the drug NE3107.
BioVie (BIVI) has revealed promising data from trials of NE3107, a drug targeting symptoms of Parkinson’s and Alzheimer’s diseases. The company plans to present the findings at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 in Lisbon, Portugal.
NE3107 Shows Promise in Parkinson’s and Alzheimer’s Disease
In a Phase 2a trial for Parkinson’s Disease, patients treated with NE3107 alongside standard carbidopa/levodopa therapy demonstrated significant improvements in non-motor symptoms like sleep/fatigue and motor control. The trial showcased a noteworthy decrease in the Non-Motor Symptom Scale (NMSS) score among NE3107-treated patients, contrasting with a deterioration in symptoms observed in the placebo group.
Moreover, the trial data suggested a potential synergy between NE3107 and levodopa, particularly advantageous for Parkinson’s patients below 70 years of age.
A Phase 3 trial exploring NE3107’s efficacy in mild to moderate Alzheimer’s Disease cases revealed encouraging trends in cognitive and functional measures, albeit not reaching statistical significance. After excluding data from sites with protocol violations, the analysis revealed that the remaining patient cohort exhibited slower rates of decline across various cognitive scales, alongside improvements in metabolic and inflammatory biomarkers.
Principal Component Analysis from the trial suggested that NE3107 might influence physiological processes in a manner consistent with reduced neurocognitive deterioration. This signifies the potential for NE3107 to address underlying biological factors associated with Alzheimer’s progression.
BioVie’s research into NE3107 highlights its potential to modulate inflammation and insulin sensitivity within the brain, potentially slowing disease progression and improving patient outcomes. While further research is needed, these results contribute to the growing evidence supporting NE3107’s therapeutic promise.
BioVie (NASDAQ: BIVI) Stock Movement
BIVI stock soared 52.42% to close at $1.89 on Friday. The traders had exchanged hands with 91,622,229 (91.62 million) shares compared to the average daily trading volume of 398.15K.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
